Seres Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Seres Therapeutics, Inc. carries a market capitalization of 55.39M, placing it among publicly traded companies globally. Its enterprise value stands at 118.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 55.39M |
| Enterprise Value | 118.59M |
Share Statistics
Seres Therapeutics, Inc. currently has 9.83M shares outstanding.
| Shares Outstanding | 9.83M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Seres Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 40.48. The price-to-sales ratio is 39.17, and the price-to-book ratio stands at 2.25.
| PE Ratio | 40.48 |
| PS Ratio | 39.17 |
| PB Ratio | 2.25 |
| P/TBV Ratio | 2.25 |
| P/FCF Ratio | -1.44 |
| P/OCF Ratio | -1.44 |
Enterprise Valuation
| EV / Sales | 62.98 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 134.38 |
Financial Position
Seres Therapeutics, Inc. maintains a current ratio of 2.11, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.11 |
| Quick Ratio | 2.04 |
| Debt / Equity | 164.02 |
| Debt / EBITDA | -0.76 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -66.57 |
| Return on Assets (ROA) | -18.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -16.86 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Seres Therapeutics, Inc.'s stock has declined approximately -69.57447% over the past 52 weeks. The 50-day moving average sits at 5.49, while the 200-day moving average is 9.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | -69.57447% |
| 50-Day Moving Average | 5.49 |
| 200-Day Moving Average | 9.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Seres Therapeutics, Inc. generated 1.88M in revenue and converted that into -22.46M in net income, yielding earnings per share of -2.40. EBITDA reached -74.78M, while operating income came in at -78.23M.
| Revenue | 1.88M |
| Gross Profit | 555,000.00 |
| Operating Income | -78.23M |
| Pretax Income | -22.46M |
| Net Income | -22.46M |
| EBITDA | -74.78M |
| EBIT | -78.23M |
| Earnings Per Share (EPS) | -2.40 |
Balance Sheet
Seres Therapeutics, Inc. holds 15.59M in cash and equivalents against 56.64M in total debt, resulting in a net debt position of -15.59M. Total book value stands at 34.53M, with working capital of 22.32M providing operational flexibility.
| Cash & Cash Equivalents | 15.59M |
| Total Debt | 56.64M |
| Net Debt | -15.59M |
| Equity (Book Value) | 34.53M |
| Book Value Per Share | 3.51 |
| Working Capital | 22.32M |
Cash Flow
Seres Therapeutics, Inc. produced -51.26M in operating cash flow over the past twelve months. After subtracting -37,000.00 in capital expenditures, free cash flow totaled -51.29M - equivalent to -5.49 per share.
| Operating Cash Flow | -51.26M |
| Capital Expenditures | -37,000.00 |
| Free Cash Flow | -51.29M |
| FCF Per Share | -5.49 |
Margins
Seres Therapeutics, Inc. operates with a gross margin of 29.47, reflecting its pricing power and cost economics. The operating margin of -4,154.38 and net profit margin of -1,192.94 provide insight into operational efficiency.
| Gross Margin | 29.47 |
| Operating Margin | -4,154.38 |
| Pretax Margin | -1,192.94 |
| Profit Margin | -1,192.94 |
| EBITDA Margin | -3,971.22 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -19.17 |
| FCF Yield | -69.31 |
Stock Splits
Seres Therapeutics, Inc.'s most recent stock split took place on April 22, 2025 with a 20:1 split ratio.
| Last Split Date | 4/22/2025 |
| Split Ratio | 20:1 |
Scores
Seres Therapeutics, Inc. posts an Altman Z-Score of -15.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.18 |